(Q34037747)

30 July 2017

Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century (English)

1 reference

30 July 2017

1 reference

1 reference

neoplastic stem cells

1 reference

Samuel A Williams

1

1 reference

30 July 2017

Wade C Anderson

series ordinal

2

1 reference

30 July 2017

Marianne T Santaguida

series ordinal

3

1 reference

30 July 2017

Scott J Dylla

series ordinal

4

1 reference

30 July 2017

5 August 2013

1 reference

30 July 2017

Laboratory Investigation

1 reference

30 July 2017

93

1 reference

30 July 2017

9

1 reference

30 July 2017

970-982

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.2013.92

30 July 2017

0 references

cites work

The paradox of response and survival in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Strategies to eliminate cancer stem cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

AACR Cancer Progress Report 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Small cell lung cancer: have we made any progress over the last 25 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

The tissue is the issue: personalized medicine for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Genome sequencing and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Screening for cancer with molecular markers: progress comes with potential problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Deconstructing the molecular portraits of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Investigative pathology: leading the post-genomic revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Designing transformative clinical trials in the cancer genome era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Whole-genome cancer analysis as an approach to deeper understanding of tumour biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Next-generation sequencing in the clinic: are we ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Molecular profiling of patient-derived breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Patient-derived tumour xenografts as models for oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Cancer stem cells and self-renewal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Cancer stem cell definitions and terminology: the devil is in the details.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

De novo discovery of mutated driver pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Economics of new oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Primary Bioassay of Human Tumor Stem Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Do cell lines in vitro reflect the properties of the tumours of origin? A study of lines derived from human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

A history of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Applications and limitations of genetically modified mouse models in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Beyond bevacizumab: antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Human tumor xenografts as model for drug testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Stem cell gene expression programs influence clinical outcome in human leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Separating stem cells by flow cytometry: reducing variability for solid tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Phenotypic characterization of human colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Identification and expansion of human colon-cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Association of reactive oxygen species levels and radioresistance in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Cancer stem cells: Models, mechanisms and implications for improved treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

The evolving concept of cancer and metastasis stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Cells of origin in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

The biology of normal and neoplastic stem cells in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Insights into the stem cells of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Polyclonal origin of colonic adenomas in an XO/XY patient with FAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Pre-tumour clones, periodic selection and clonal interference in the origin and progression of gastrointestinal cancer: potential for biomarker development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Hematopoietic stem cell heterogeneity: subtypes, not unpredictable behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Further evidence favoring the concept of the stem cell in ascites tumors of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Studies of the dissemination and quantitative transplantation of a lymphocytic leukaemia of CBA mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Cancer Facts & Figures 2012. American Cancer Society (ACS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

A Quantitative Assay for the Number of Murine Lymphoma Cells capable of Proliferation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

Are companion diagnostics useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Cancer biomarkers, companion diagnostics and personalized oncology

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Cancer genomics: from discovery science to personalized medicine

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

The landscape of cancer genes and mutational processes in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Methods for evaluating the morphological and immunohistochemical properties of human tumor colonies grown in soft agar

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Immune-Deficient Mice as Models for Human Hematopoietic Disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Anoikis: roadblock to cell transplantation?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.92

7 January 2021

10.1038/LABINVEST.2013.92

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference